SCHEDULE 13G/A: Wellington Management Reduces Stake in Nurix Therapeutics Below 5%

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 4.18% in Nurix Therapeutics, Inc. as of March 31, 2025.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP, filed an Amendment No. 1 to Schedule 13G.
• The filing reports their beneficial ownership in Nurix Therapeutics, Inc. Common Stock.
• As of March 31, 2025, the aggregate amount beneficially owned by the reporting persons is 3,188,742 shares.
• This represents 4.18% of the class of Nurix Therapeutics, Inc. Common Stock.
• The reporting persons have shared voting power over 2,373,277 shares and shared dispositive power over 3,188,742 shares.
• They hold no sole voting or dispositive power.
• The securities are owned of record by clients of Wellington Investment Advisers, and no single client is known to have beneficial ownership of more than five percent of the class.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing disclosing a change in beneficial ownership, not containing performance or forward-looking statements from the issuer.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• The reporting persons certify that, to the best of their knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing reflects a change in a significant institutional investor's stake in a biotechnology company, Nurix Therapeutics, Inc. Such changes are part of the normal course of portfolio management by large investment firms.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional investor reducing its stake below the 5% reporting threshold may influence investor sentiment and potentially the stock price, as it could be interpreted as a change in conviction by a major holder.

Next Steps

• NA

Key Dates

Keywords

Nurix Therapeutics, Wellington Management Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Advisers